Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial

PURPOSE: No previous clinical trial has been conducted for patients with neuroblastoma associated opsoclonus myoclonus ataxia syndrome (OMA), and current treatment is based on case reports. To evaluate the OMA response to prednisone and risk-adapted chemotherapy and determine if the addition of intr...

Descripción completa

Detalles Bibliográficos
Autores principales: de Alarcon, Pedro A., Matthay, Katherine K., London, Wendy B., Naranjo, Arlene, Tenney, Sheena C., Panzer, Jessica A., Hogarty, Michael D., Park, Julie R., Maris, John M., Cohn, Susan L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783315/
https://www.ncbi.nlm.nih.gov/pubmed/29376112
http://dx.doi.org/10.1016/S2352-4642(17)30130-X

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783315/
https://www.ncbi.nlm.nih.gov/pubmed/29376112
http://dx.doi.org/10.1016/S2352-4642(17)30130-X

Ejemplares similares